RET and non-small cell lung carcinoma: The landmark phase I/II multi-cohort open-label trial that led to FDA approval for selpercatinib was LIBRETTO-00, where patients were either treatment-naïve or previously received platinum-based chemotherapy for their RET fusion NSCLC.